Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Access Pharmaceuticals has signed an agreement with a pharmaceutical firm to develop its CobaCyte and CobOral technology for the targeted delivery of RNAi therapeutics.
Subscribe to our email newsletter
Access Pharma will offer its CobaCyte and CobOral technology to the pharma firm for assessing gene knockdown after oral and intravenous administration.
Any successful formulation developed will be jointly owned by the two companies and subject to a subsequent full licensing agreement.
Access Pharma president and CEO Jeffrey Davis said the signing of this agreement serves as further validation of their previous work related to their CobaCyte technology’s ability to deliver inactivated siRNA particles to disease target sites.